According to reports from Business Standard, Bacil Pharma reported a standalone net profit of ₹0.04 crore for the quarter ended December 2025, marking a significant improvement from the net loss of ₹0.06 crore recorded during the corresponding quarter of the previous year. This represents a turnaround in the company's financial performance during the December 2025 quarter.
As reported by Business Standard, the company reported zero sales for both the quarter ended December 2025 and the previous quarter ended December 2024. The absence of reported sales figures indicates that Bacil Pharma has not generated any revenue during these quarters, which may be attributed to operational challenges or strategic business decisions.
According to the financial data reported by Business Standard, the company's financial position showed improvement when compared to the same quarter in the previous year. The ₹0.04 crore profit in December 2025 represents a positive shift from the ₹0.06 crore loss recorded in December 2024, demonstrating the company's ability to reduce its operational losses despite maintaining zero sales revenue.
Recent market data shows Bacil Pharma stock trading at ₹0.00 on various exchanges, reflecting the company's current financial position. The stock's performance aligns with the company's reported quarterly results, indicating that market participants are responding to the company's improved financial metrics despite maintaining zero sales revenue.
